Skip to main content


This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍
Emilio Martin Mola @emartinmola( View Tweet )
Oct 16, 2021

Hepatitis B Reactivation with Rituximab and Abatacept

Oct 12, 2021

Hepatitis B reactivation is an uncommon complication of biologic therapy use. Now, a serologic study of  rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without hepatitis B antibody (HBsAb) positivity.

Read Article

Pathways to a Psoriatic Arthritis Diagnosis

Oct 06, 2021

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different

Read Article

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in

Read Article

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article

Not All Immunosuppression Alters Vaccine Immunogenicity

Sep 02, 2021

Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT)

Read Article

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article

The Predictive Value of Morning Stiffness

Aug 25, 2021

A prospective study evaluated the value and associations with morning stiffness in patients with clinically suspect arthralgia, and found that the presence of morning stiffness increases the odds of inflammation (as detected by CRP and MRI synovitis).

Read Article

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

MedPage Today
Aug 24, 2021

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Read Article

RheumNow Podcast – Driving in Pain (8.20.2021)

Aug 20, 2021

You know, I'm a very good driver. We all think we're great drivers - but consider what it's like to drive in pain: would you be a good driver? Also, I want you to consider the diagnosis of calcium pyrophosphate dihydrate disease (CPPD). But first, let's look at a study out of Scotland, looking

Read Article

Tocilizumab in Refractory Skin and Joint Scleroderma

Aug 18, 2021

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.

TCZ is currently FDA approved for use in SSc

Read Article

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Aug 06, 2021

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article

Combo Methotrexate and Leflunomide Safety in RA

Jul 28, 2021

Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide. A recent study of combination therapy with MTX and LEF underscores the efficacy and safety of this approach and

Read Article

Cardiovascular Prevention Lacking in Rheumatoid Arthritis

Jul 28, 2021

An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).

Read Article

Canakinumab Fails to Improve COVID-19 Survival

Jul 20, 2021

JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.

Other studies have suggested that the use of IL-1 inhibitors (anakinra) may improve COVID outcomes,

Read Article

Arthritis as a Harbinger of Pediatric Cancer

Jul 15, 2021

Lancet Rheumatology has published a cohort analysis showing that a small but significant subset of children presenting with arthralgia or arthritis may have a pediatric malignancy.

This multicentre study sought to identify articular presentations of children manifesting

Read Article

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

Neuropsychiatric Events Common in Lupus

Jun 30, 2021

Neuropsychiatric (NP-SLE) or CNS lupus events range from mild to severe; several recent studies have noted that NPS lupus is common and should be screened for.

A metanalysis of the literature finds 22 studies wherein the mean frequency of NPSLE ranged from 10.6% to 96.4%. When researchers with

Read Article

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jun 25, 2021

Dr. Jack Cush reviews this week’s news and journal reports featured on

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

How Do You Measure Success When It Comes to SLE?

Jun 10, 2021

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 05, 2021
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow
Dr. Rachel Tate @uptoTate( View Tweet )
Jun 04, 2021
So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow
David Liew @drdavidliew( View Tweet )
Jun 03, 2021
Insights in RA and colon: NaĂŻve RA patients -higher degree of intestinal permeability vs age and sex matched ctrls in colonic biopsies -higher serum levels of bacterial translocation markers (LBP and CD14s); reduced in resp to DMARDs. #EULAR2021 @RheumNow #OP0035 @ClaireDaien

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 02, 2021